Innovative sustainable approaches in antiparasitic drug discovery: towards a One Health approach

The main objective of OneHealthdrugs is to achieve optimal drugs against vector borne parasitic diseases contributing to health and sustainability for humans, animals, and the environment simultaneously. This meeting organized by WG2 Leaders addresses how we can approach the sustainability principles in antiparasitic drug discovery under ongoing and future program . This is a general concept and encompasses natural products, sustainable drug design, greener synthetic methods for drug synthesis, waste valorisation and any other strategy and concept that you may think that could promote easy access to drugs for parasitic diseases always keeping in mind the OneHealth triptych (human, animals, environment). It is worth noting that it is not exclusively necessary that the sustainability concepts are already included and presented in your ongoing work, it can also be a perspective view. We should be inspirational  and let people understand our vision towards sustainability towards the future. 

Programme

14:00 - 14:05

Theodora Calogeropoulou (National Hellenic Research Foundation, EL) and Federica Pellati (Universitá di

Modena e Reggio Emilia, IT)

Welcome

14:05 – 14:10

Maria Paola Costi (Universita di Modena e Reggio Emilia, IT)

Introduction to COST Action CA21111 OneHealthDrugs

Session chair: Federica Pellati (Universitá di Modena e Reggio Emilia, IT)

14:10 – 14:30

Luiz Antonio Soares Romeiro (University of Brasília, Brasilia, Brazil)

O Luxo do Lixo: Medicinal Chemistry Strategies for Sustainable Antiparasitic Drug Discovery

14:30 – 14.50

Denis Sarigiannis (Aristotle University of Thessaloniki, & National Hellenic Research Foundation, EL )

Exposome based development of Safe and Sustainable by Design (SSbD) antiparasitic drugs

14:50 – 15:10

Harry P. de Koning (College of Medical, Veterinary and Life Sciences, University of Glasgow, UK)

Bee propolis as a sustainable, local source of antikinetoplastid agents

15.10 – 15.40

Round table discussion on “Sustainability track for antiparasitic drug discovery”

Panel members: Maria Paola Costi (Universitá di Modena e Reggio Emilia, IT), Richard Marhoefer (Boehringer-

Ingelheim, DE), Maria Laura Bolognesi (Universitá di Bologna, IT)

Topics to be discussed:

• What criteria define a drug discovery process sustainable?

• Which steps of the drug discovery process are considered more critical for sustainability?

• What is the connection between One Health and sustainability?

Session chair: I. Papanastasiou (National Kapodistrian University of Athens, EL)

15.40 – 16.00

Panagiotis Karanis (University of Nicosia Medical School, CY & Medical Faculty, University of Cologne, DE)

The challenge of the in vitro culture of Cryptosporidium and its application for the development of anti-parasitic

drugs and therapy of cryptosporidiosis.

16.00 – 16.20

Teita Myrseli (Department of Control of Infectious Diseases, Institute of Public Health, Tirana, Albania)

The situation of leishmaniasis in Albania, factors that facilitate the spread and the importance of innovative

antiparasitic drug discovery.

16.20 – 16.40

Sandra Gemma (Department of Biotechnology, Chemistry and Pharmacy, University of Siena, IT)

Exploration of heterocyclic/oxygenated chalcones as antileishmanial agents and pilot investigation of a greener

synthetic approach

16.40 – 17.00

Giulia Malpezzi (Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena, IT)

Preclinical investigation of the mechanism of H80 lead action versus miltefosine through imaging and mass

spectrometry proteomics to facilitate a more sustainable approach in lead development and clinical translation.

17.00 – 17.05

Closing

To register at the workshop, pelase access he following Google Form: https://docs.google.com/forms/d/e/1FAIpQLSciP6KaN9nGOAqJqrXxmpUj1ahulz_FkxqnMt9_zrz7f4ut3Q/viewform?usp=sharing